Teva Pharmaceutical Industries Ltd. $TEVA is Sound Shore Management Inc. CT’s Largest Position

Posted by Francis Steltz on Jul 20th, 2026

Sound Shore Management Inc. CT lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 9.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,885,683 shares of the company’s stock after selling 424,223 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 3.9% of Sound Shore Management Inc. CT’s portfolio, making the stock its largest holding. Sound Shore Management Inc. CT’s holdings in Teva Pharmaceutical Industries were worth $117,037,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TEVA. Aster Capital Management DIFC Ltd purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $25,000. Cornerstone Planning Group LLC raised its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after acquiring an additional 755 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust boosted its position in shares of Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $32.00 on Monday. The company has a market capitalization of $36.79 billion, a P/E ratio of 24.06, a PEG ratio of 3.38 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock has a 50 day moving average price of $33.76 and a two-hundred day moving average price of $32.70.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $3.98 billion for the quarter. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TEVA shares. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $41.78.

Read Our Latest Research Report on Teva Pharmaceutical Industries

Insider Activity

In other news, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. The trade was a 34.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares in the company, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.